MX2023009445A - Compuestos de heterociclos tetraciclicos utiles como inhibidores de la integrasa del vih. - Google Patents
Compuestos de heterociclos tetraciclicos utiles como inhibidores de la integrasa del vih.Info
- Publication number
- MX2023009445A MX2023009445A MX2023009445A MX2023009445A MX2023009445A MX 2023009445 A MX2023009445 A MX 2023009445A MX 2023009445 A MX2023009445 A MX 2023009445A MX 2023009445 A MX2023009445 A MX 2023009445A MX 2023009445 A MX2023009445 A MX 2023009445A
- Authority
- MX
- Mexico
- Prior art keywords
- tetracyclic heterocycle
- heterocycle compounds
- compounds useful
- hiv integrase
- integrase inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163149927P | 2021-02-16 | 2021-02-16 | |
| PCT/US2022/016261 WO2022177840A1 (en) | 2021-02-16 | 2022-02-14 | Tetracyclic heterocycle compounds useful as hiv integrase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023009445A true MX2023009445A (es) | 2023-08-25 |
Family
ID=80625127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023009445A MX2023009445A (es) | 2021-02-16 | 2022-02-14 | Compuestos de heterociclos tetraciclicos utiles como inhibidores de la integrasa del vih. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11958864B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4294813B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024507788A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230147131A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117083282B (cg-RX-API-DMAC7.html) |
| AR (1) | AR124868A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022223241B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3208396A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3048138T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023009445A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202246286A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022177840A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240151256A (ko) | 2019-03-22 | 2024-10-17 | 길리애드 사이언시즈, 인코포레이티드 | 가교된 트리시클릭 카르바모일피리돈 화합물 및 그의 제약 용도 |
| EP4110783A1 (en) | 2020-02-24 | 2023-01-04 | Gilead Sciences, Inc. | Tetracyclic compounds for treating hiv infection |
| CN116390924B (zh) | 2020-09-30 | 2025-11-07 | 吉利德科学公司 | 桥连三环氨基甲酰基吡啶酮化合物及其用途 |
| CR20260070A (es) | 2021-01-19 | 2026-04-24 | Gilead Sciences Inc | COMPUESTOS DE PIRIDOTRIAZINA SUSTITUIDOS Y USOS DE ESTOS (Divisional 2023-0315) |
| TWI856796B (zh) | 2022-04-06 | 2024-09-21 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| WO2024226485A1 (en) * | 2023-04-28 | 2024-10-31 | Merck Sharp & Dohme Llc | Delivery devices for anti-hiv compounds |
| WO2026101812A1 (en) * | 2024-11-07 | 2026-05-15 | Merck Sharp & Dohme Llc | Hiv integrase inhibitors for treatment of hiv infection |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2660239B1 (en) * | 2008-07-25 | 2016-11-23 | VIIV Healthcare Company | Chemical compounds as synthetic intermediates |
| WO2010011812A1 (en) * | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
| ES2395705T3 (es) * | 2008-07-25 | 2013-02-14 | Glaxosmithkline Llc | Compuestos químicos |
| LT2620436T (lt) * | 2010-09-24 | 2018-08-10 | Shionogi & Co., Ltd. | Pakeistojo policiklinio karbamoilpiridono darinio provaistas |
| WO2017113288A1 (en) * | 2015-12-31 | 2017-07-06 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as hiv integrase inhibitors |
| JOP20190130A1 (ar) | 2016-12-02 | 2019-06-02 | Merck Sharp & Dohme | مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv) |
| WO2018140368A1 (en) * | 2017-01-26 | 2018-08-02 | Merck Sharp & Dohme Corp. | Substituted quinolizine derivatives useful as hiv integrase inhibitors |
-
2022
- 2022-02-14 US US17/670,689 patent/US11958864B2/en active Active
- 2022-02-14 CA CA3208396A patent/CA3208396A1/en active Pending
- 2022-02-14 AU AU2022223241A patent/AU2022223241B2/en active Active
- 2022-02-14 MX MX2023009445A patent/MX2023009445A/es unknown
- 2022-02-14 EP EP22707560.3A patent/EP4294813B1/en active Active
- 2022-02-14 AR ARP220100289A patent/AR124868A1/es unknown
- 2022-02-14 CN CN202280022034.3A patent/CN117083282B/zh active Active
- 2022-02-14 ES ES22707560T patent/ES3048138T3/es active Active
- 2022-02-14 TW TW111105302A patent/TW202246286A/zh unknown
- 2022-02-14 KR KR1020237031339A patent/KR20230147131A/ko active Pending
- 2022-02-14 JP JP2023548941A patent/JP2024507788A/ja active Pending
- 2022-02-14 WO PCT/US2022/016261 patent/WO2022177840A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022177840A1 (en) | 2022-08-25 |
| CN117083282A (zh) | 2023-11-17 |
| ES3048138T3 (en) | 2025-12-09 |
| JP2024507788A (ja) | 2024-02-21 |
| KR20230147131A (ko) | 2023-10-20 |
| CA3208396A1 (en) | 2022-08-25 |
| CN117083282B (zh) | 2026-05-29 |
| AR124868A1 (es) | 2023-05-10 |
| US11958864B2 (en) | 2024-04-16 |
| EP4294813A1 (en) | 2023-12-27 |
| AU2022223241B2 (en) | 2026-04-30 |
| US20220259227A1 (en) | 2022-08-18 |
| AU2022223241A1 (en) | 2023-08-24 |
| TW202246286A (zh) | 2022-12-01 |
| EP4294813B1 (en) | 2025-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR124868A1 (es) | Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih | |
| DOP2019000140A (es) | Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih | |
| DOP2023000168A (es) | Compuestos antivirales que contienen nitrilo | |
| UY37795A (es) | Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 | |
| UY39032A (es) | Compuestos heterocíclicos como agentes antivirales | |
| ECSP16016726A (es) | Derivados de quinolizina sustituidos útiles como inhibidores de integrasa del vih | |
| CO2021004679A2 (es) | Inhibidores de la replicación del virus de la inmunodeficiencia humana | |
| MX2020011317A (es) | Compuestos heterociclicos triciclicos utiles como inhibidores de la integrasa de vih. | |
| UY38559A (es) | Inhibidores de la replicación del virus de la inmunodeficiencia humana | |
| UY38614A (es) | Derivados de benzodiazepinas como inhibidores del rsv | |
| MX2019006449A (es) | Compuestos heterociclicos triciclicos utiles como inhibidores de la integrasa del virus de inmunodeficiencia humana (vih). | |
| MX2012006297A (es) | Uso topico hidroxitirosol y derivados para la prevencion de la infeccion por vih. | |
| UY39642A (es) | Compuestos heterocíclicos antivirales | |
| CL2022002405A1 (es) | Inhibidores de la replicación del virus de inmunodeficiencia humana | |
| AR127470A1 (es) | Inhibidores de lrrk2 | |
| CO2017003838A2 (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos | |
| CO2025003090A2 (es) | Compuestos de piridinona sustituida como inhibidores de cbl-b | |
| CL2025000672A1 (es) | Compuestos derivados de aminopirimidina, inhibidores de cdk2; composición farmacéutica; uso para tratar cáncer. | |
| MX2021009584A (es) | Nuevos derivados de triterpeno como inhibidores del virus de la inmunodeficiencia humana (vih). | |
| ECSP24007193A (es) | Compuestos pirimidínicos para usar como inhibidores de map4k1 | |
| ECSP23075535A (es) | Compuestos cíclicos y métodos de uso | |
| UY40025A (es) | Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno, y composiciones far | |
| MX2023007716A (es) | Procedimientos de tratamiento de enfermedades fibroticas. | |
| MX2025014666A (es) | Forma cristalina de sal sodica de derivados de piridona carbamoilica policiclica, su metodo de preparacion y aplicacion | |
| UY39738A (es) | Compuestos antivirales que contienen nitrilo |